Abstract
CONTEXT: Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). Common adverse effects include an acute-phase reaction, infections and autoimmune diseases, including thyroid disorders. SETTING: Patients from two phase 3 trials (CARE MS 1 and 2, n=15) were studied in a clinical research center. PATIENTS: Five out of fifteen patients developed severe Graves’ disease after a mean of 32 months following the first alemtuzumab treatment. MAIN OUTCOME MEASURES: Thyroid function tests and thyroid antibodies were assessed. In addition, endocrine tests and measurement of antibodies indicative of autoimmunity were performed. RESULTS: Of the five patients developing Graves’ disease, four patients were initially treated with antithyroid drugs, whereas the fifth patient had mild and self-limiting hyperthyroidism. Of the four patients treated with antithyroid drugs, one is currently under medical treatment in a dose-reducing regimen, whereas three patients underwent near-total thyroidectomy 2, 12 and 16 months later. Two patients developed endocrine ophthalmopathy. Pituitary, adrenal and gonadal hormones were normal in all patients. While four out of five patients were positive for several other autoantibodies, none developed other autoimmune diseases. CONCLUSION: Since autoimmune thyroid disease is common after alemtuzumab treatment for MS, pretreatment screening and careful follow-up may allow for early diagnosis and treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ, 2010 B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 30: 99–105.
Buggins AG, Mufti GJ, Salisbury J, et al, 2002 Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 100: 1715–1720.
Coles AJ, Cox A, Le Page E, et al, 2006 The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98–108.
Coles AJ, Compston DA, Selmaj KW, et al, CAMMS 223 Trial Investigators, 2008 Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801.
Cohen JA, Coles AJ, Arnold DL, et al, CARE-MS I investigators, 2012 Alemtuzumab versus interferon beta la as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380: 1819–1828.
Coles AJ, Twyman CL, Arnold DL, et al, CARE-MS II investigators, 2012 Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet 380: 1829–1839.
Hirst CL, Pace A, Pickersgill TP, et al, 2008 Campath 1-H treatment in patients with aggressive remitting multiple sclerosis. J Neurol 255: 231–238.
Klotz L, Meuth SG, Wiendl H, 2012 Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 142: 25–30.
Coles AJ, Wing M, Smith S, et al, 1999 Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691–1695.
Sherer Y, Shoenfeld Y, 1998 Autoimmune diseases and autoimmune post-bone marrow transplantation. Bone Marrow Transplant 22: 873–881.
Weetman AP, 2009 “Ioning out thyroid autoimmunity”. Endocr Pract 15: 53–55.
Sipos JA, Kahaly GJ, 2012 Imaging of thyreotoxicosis. Am J Med 125: 1–2.
Wiersinga WM, Perros P, Kahaly GJ, et al, 2006 Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387–389.
Castagnetta L, Granata OM, Traina A, et al, 2002 A role for sex steroids in autoimmune diseases: a working hypothesis and supporting data. Ann NY Acad Sci 966: 193–203.
Estienne V, Duthoit C, Reichert M, et al, 2002 Androgen-dependent expression of FCgammaRIIB2 by thyrocytes from patients with autoimmune Graves’ disease: a possible molecular clue for sex dependence of autoimmune disease. FASEB J 16: 1087–1092.
Fairweather D, Frisancho-Kiss S, Rose NR, 2008 Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173: 600–609.
Pearl JP, Parris J, Hale DA, et al, 2005 Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5: 465–474.
Bahn RS, 2010 Graves’ ophthalmopathy. N Engl J Med 362: 726–738.
Eckstein A, Esser J, Mann K, Schott M, 2010 Clinical value of TSH receptor antibodies measurement in patients with Graves’ orbitopathy. Pediatr Endocrinol Rev 7: Suppl 2: 198–203.
Iglesias P, Devora O, Garcia J, et al, 2010 Severe hyperthyroidism: aetiology, clinical features and treatment outcome. Clin Endocrinol 72: 551–557.
Aranha AA, Amer S, Reda ES, et al, 2013 Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review. Endocr Pract 11: 1–25.
Glick AB, Wodzinski A, Fu P, et al, 2013 Impairment of regulatory T cell function in autoimmune thyroid disease. Thyroid 23: 871–878.
Jones JL, Phuah CL, Cox AL, et al, 2009 IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119: 2052–2061.
Hu Y, Turner MJ, Shields J, et al, 2009 Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse. Immunology 128: 260–270.
Watanabe M, Nakamura Y, Matsuzuka F, et al, 2008 Decrease of intrathyroidal CD161+Valpha24+Vbeta11+NKT cells in Graves’ disease. Endocr J 55: 199–203.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsourdi, E., Gruber, M., Rauner, M. et al. Graves’ disease after treatment with Alemtuzumab for multiple sclerosis. Hormones 14, 148–153 (2015). https://doi.org/10.14310/horm.2002.1501
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1501